Abstract:Background Anti-tumoral immunotherapy of anti- programmed cell death protein-1 (PD-1)/programmed cell death protein-ligand 1 (PD-L1) immune checkpoint therapy demonstrated the efficacy and tolerability in patients with lung cancer. Apart from inhibitory checkpoints, OX40, the co-stimulatory receptor related to T cell priming and proliferation, was valued identically. In this study, the relationship between OX40/OX40L among PD-1/PD-L1 and other immunological factors, as well as its role serving as the potential prognostic biomarker were analyzed in NSCLC. Methods We investigated the relationship between OX40/OX40L, PD-1/PD-L1 and TILs in surgical samples from 139 patients with NSCLC by immunohistochemistry (IHC). Factors related to OX40/OX40L expression were analyzed by logistic regression and multi-linear regression. Cox analysis was also performed to find the influencing factors. Survival analysis was conducted in order to testify its role in predicting patients’ prognosis. Results The TILs OX40/OX40L expression was negatively correlated with the PD-1/PD-L1 expression. PD-1expression was negatively correlated with the TILs OX40 expression (R = 0.250, [p = 0.003]), it was also negatively correlated with the TILs OX40L expression (R = 0.386, [p = 0.0001]). PD-1expression was positively correlated with TILs grades and negatively correlated with the TILs OX40L expression (R = 0.531, [X1, 95%CI 3.552-8.176, p = 0.0001; X2, 95%CI 0.216-0.683], [p = 0.0001]). The expression of TILs OX40 varied significantly among tumor OX40, OX40L, PD-1, PD-L1, TILs and pathology types. Tumor OX40L expression, TILs OX40L expression, PD-1 expression, PD-L1 expression and TILs were considered as risk factors for TILs OX40 expression. The staging and TILs OX40L were considered as risk factors for overall survival (OS) while stage and gender were risk factors for recurrence-free survival (RFS). The low-expression of OX40 was related to longer RFS, OS and better prognosis. Conclusions OX40 plays a pivotal role in NSCLC, which was closely correlated with immunological factors, RFS and prognosis. Legal entity responsible for the study The authors. Funding This study was supported in part by a grant from National Natural Science Foundation of China (81802255), Shanghai Pujiang Program (17PJD036) and a grant from Shanghai Municipal Commission of Health and Family Planning Program (20174Y0131). National key research & development project (2016YFC0902300). Major disease clinical skills enhancement program of three year action plan for promoting clinical skills and clinical innovation in municipal hospitals, Shanghai Shen Kang Hospital Development Center Clinical Research Plan of SHDC (16CR1001A). The fundamental research funds for the central universities. Disclosure All authors have declared no conflicts of interest.

Hypoxia induced high expression of thioredoxin interacting protein (TXNIP) in non-small cell lung cancer and its prognostic effect.

Identification of Thioredoxin-1 As a Biomarker of Lung Cancer and Evaluation of Its Prognostic Value Based on Bioinformatics Analysis

Comprehensive Analysis of Hypoxia-Related Gene Signature in Cervical Cancer

Decreased expression of TXNIP is associated with poor prognosis and immune infiltration in kidney renal clear cell carcinoma

Expression of hypoxia inducible factor-1α in non-small cell lung cancer

TXNIP Gene in Tumorigenesis and Metastasis

Research Progress of TXNIP as a Tumor Suppressor Gene Participating in the Metabolic Reprogramming and Oxidative Stress of Cancer Cells in Various Cancers

OX40 and OX40L Protein Expression of Tumor Infiltrating Lymphocytes in Non-Small Cell Lung Cancer and Its Role in Clinical Outcome and Relationships with Other Immune Biomarkers

ITCH Facilitates Proteasomal Degradation of TXNIP in Hypoxia‐ Induced Lung Cancer Cells

Silencing thioredoxin induces liver cancer cell senescence under hypoxia.

Abstract P2-16-02: TXNIP-dependent tumor suppressive pathways in breast cancer growth and progression

163POX40/OX40L protein expression in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers

Meta-analysis of Immunohistochemical Expression of Hypoxia Inducible Factor-1Α As a Prognostic Role in Gastric Cancer.

Expression and clinical significance of hypoxia-inducible factor 1 in non small cell lung cancer

Suppression of pancreatic cancer proliferation through TXNIP-mediated inhibition of the MAPK signaling pathway

The Expression and Prognostic Value of Hypoxia-Inducible Factor-1Α and P53 in Non-Small Cell Lung Carcinoma

The Role of TXNIP in Cancer: a Fine Balance Between Redox, Metabolic, and Immunological Tumor Control

Role of TXNDC5 in Tumorigenesis of Colorectal Cancer Cells: in Vivo and in Vitro Evidence

Neutrophils correlate with hypoxia microenvironment and promote progression of non-small-cell lung cancer

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer

HBXIP Suppression Reduces Cell Proliferation and Migration and Its Overexpression Predicts Poor Prognosis in Non-Small-cell Lung Cancer